Somatic molecular analysis augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool by Sakhdari, Ali et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2019-06-18 
Somatic molecular analysis augments cytologic evaluation of 
pancreatic cyst fluids as a diagnostic tool 
Ali Sakhdari 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Cell Biology Commons, Diagnosis Commons, Fluids and 
Secretions Commons, Neoplasms Commons, and the Oncology Commons 
Repository Citation 
Sakhdari A, Moghaddam PA, Ok CY, Walter O, Tomaszewicz K, Caporelli M, Meng X, LaFemina J, Whalen 
GF, Belkin E, Zivny J, Wassef WY, Woda BA, Hutchinson L, Cosar EF. (2019). Somatic molecular analysis 
augments cytologic evaluation of pancreatic cyst fluids as a diagnostic tool. Open Access Articles. 
https://doi.org/10.18632/oncotarget.26999. Retrieved from https://escholarship.umassmed.edu/oapubs/
3895 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Oncotarget4026www.oncotarget.com
Somatic molecular analysis augments cytologic evaluation of 
pancreatic cyst fluids as a diagnostic tool
Ali Sakhdari1,5, Parnian Ahmadi Moghaddam1,4,6, Chi Young Ok1,5, Otto Walter1, 
Keith Tomaszewicz1, Mandi-Lee Caporelli1, Xiuling Meng1, Jennifer LaFemina2, 
Giles Whalen2, Edward Belkin3, Jaroslav Zivny3, Wahid Wassef3, Bruce A. Woda1, 
Lloyd M. Hutchinson1 and Ediz F. Cosar1
1University of Massachusetts Medical School, Department of Pathology, Worcester, MA, USA 
2University of Massachusetts Medical School, Department of Surgery, Worcester, MA, USA 
3University of Massachusetts Medical School, Department of Medicine, Worcester, MA, USA
4Massachusetts General Hospital, Department of Pathology, Boston, MA, USA
5MD Anderson Cancer Center, Department of Hematopathology, Houston, TX, USA 
6University of Texas, Health Science Center, Department of Pathology, Houston, TX, USA 
Correspondence to: Lloyd Hutchinson, email: Lloyd.Hutchinson@umassmemorial.org
Keywords: pancreatic cyst classification; non-diagnostic cytology; molecular next generation sequencing
Received: February 08, 2019    Accepted: May 20, 2019    Published: June 18, 2019
Copyright: Sakhdari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Objective: Better tools are needed for early diagnosis and classification of 
pancreatic cystic lesions (PCL) to trigger intervention before neoplastic precursor 
lesions progress to adenocarcinoma. We evaluated the capacity of molecular analysis 
to improve the accuracy of cytologic diagnosis for PCL with an emphasis on non-
diagnostic/negative specimens. 
Design: In a span of 7 years, at a tertiary care hospital, 318 PCL endoscopic 
ultrasound-guided fine needle aspirations (EUS-FNA) were evaluated by cytologic 
examination and molecular analysis. Mucinous PCL were identified based on a clinical 
algorithm and 46 surgical resections were used to verify this approach. The mutation 
allele frequency (MAF) of commonly altered genes (BRAF, CDKN2A, CTNNB1, GNAS, 
RAS, PIK3CA, PTEN, SMAD4, TP53 and VHL) was evaluated for their ability to identify 
and grade mucinous PCL. 
Results: Cytology showed a diagnostic sensitivity of 43.5% for mucinous PCL due 
in part to the impact of non-diagnostic (28.8%) and negative (50.5%) specimens. 
Incorporating an algorithmic approach or molecular analysis markedly increased the 
accuracy of cytologic evaluation. Detection of mucinous PCL by molecular analysis was 
93.3% based on the detection of KRAS and/or GNAS gene mutations (p = 0.0001). 
Additional genes provided a marginal improvement in sensitivity but were associated 
with cyst type (e.g. VHL) and grade (e.g. SMAD4). In the surgical cohort, molecular 
analysis and the proposed algorithm showed comparable sensitivity (88.9% vs. 
100%). 
Conclusions: Incorporating somatic molecular analysis in the cytologic evaluation 
of EUS-FNA increases diagnostic accuracy for detection, classification and grading of 
PCL. This approach has the potential to improve patient management.
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INTRODUCTION
Recent advances in diagnostic imaging such as 
high-resolution ultrasonography (HR-US), computed 
tomography (CT), and magnetic resonance imaging (MRI) 
have increased detection rate of pancreatic cystic lesions 
(PCL) [1]. A substantial fraction (5–10%) of these cystic 
lesions are pancreatic cystic neoplasms (PCN), [2, 3] a 
significant majority of which are mucinous neoplastic 
cysts including intraductal papillary mucinous neoplasm 
(IPMN), and mucinous cystic neoplasm (MCN). IPMN 
and MCN carry malignant potential [4–9]. IPMN and 
MCN are mucinous precursor lesions for pancreatic ductal 
adenocarcinoma (PDAC), a highly aggressive tumor 
currently with a very low survival rate [10, 11]. Early 
detection of PDAC and its precursors has the potential to 
significantly increase survival rates [12, 13]. 
Accurate and early diagnosis of PCN is important 
for the appropriate management of patients and reduction 
of cancer-specific mortality. Separation of PCN from non-
neoplastic PCL which are unlikely to require surveillance 
or surgery remains challenging. The current diagnostic 
approaches rely primarily on cytologic examination, tumor 
biomarker analysis of cyst fluid and high-resolution imaging 
[14]. The diagnostic power of imaging modalities including 
CT scan and HR-US is limited with an accuracy of 50–73% 
in differentiating neoplastic from non-neoplastic cysts [15] 
with considerable high inter- and intra-observer variability 
[16, 17]. The sensitivity of cytologic examination using EUS-
FNA for the detection of mucinous precursor lesions is only 
49 to 59% [18]. Carcinoembryonic antigen (CEA), among 
other biomarkers, has the best sensitivity (59–67%) for the 
detection of mucinous precursor lesions [18].
Guidelines have been published to assist in 
the diagnosis and management of PCL [19–21]. 
These incorporate clinical, laboratory and pathologic 
characteristics of PCL including patient age, clinical 
symptoms, pancreatic duct type and size, presence of a 
mural nodule, cytology of the cyst fluid, cyst size and 
diagnostic imaging characteristics [14, 19, 20, 22]. 
Molecular changes commonly found in PDAC, 
including abnormalities in KRAS, GNAS, SMAD4, 
CDKN2A, BRAF, PIK3CA and TP53 genes can also be 
present in precursor lesions [23–25]. We hypothesized that 
incorporating the molecular analysis into PCL cytology 
specimens may increase the diagnostic accuracy and 
may help to identify patients who require surveillance or 
consideration for surgical management. This approach 
is especially important in paucicellular specimens which 
frequently yield a non-diagnostic cytology result yet may 
contain adequate material for molecular analysis [9, 26, 27]. 
In the current study, we show that molecular analysis 
of the cyst fluid has clinical utility in identifying gene 
mutations associated with neoplastic PCLs and improves 
the sensitivity/specificity of the clinical diagnosis 
particularly in non-diagnostic cytology specimens.
RESULTS
Molecular and cytology results for patients with 
surgical resections concur with algorithm-based 
classification
Of 278 patients with PCL and paired molecular 
studies, 46 (16.5%) underwent surgical resection at our 
institution (Supplementary Table 1). The surgical pathology 
diagnoses were as follows: IPMN (n = 19, 41.3%) (main 
duct [md] - and branch duct [bd]-IPMN), MCN (n = 9, 
19.6%), PDAC (n = 8, 17.4%), SCA (n = 2, 4.3%), PNET 
(n = 3, 6.5%) and pseudocysts (n = 5, 10.9%) (Table 
1). Among IPMN, MCN or PDAC diagnoses, cytology 
yielded a correct result in 15 of 36 (41.6%) whereas 21 
cases were classified as either non-diagnostic (“ND”, 
n = 10) or negative (“NEG”, n = 11). Molecular analysis 
of preoperative cyst fluid from the IPMN/MCN/PDAC 
group with 36 surgical specimens in total, showed at least 
one mutation in KRAS or GNAS genes in 31 (86.1%), 
including 16 of the 21 (76.2%) cases incorrectly classified 
by cytology (“NEG”: n = 9, “ND”: n = 7). The sensitivity 
of molecular analysis in detecting mucinous PCN based 
on the presence of any mutation was 88.9% (32 of 36 
cases) which is significantly higher than that of cytology 
(41.6%; 15 of 36 cases; p = 0.0001, Fisher’s exact test). 
This finding is similar to the algorithmic approach for 
classifying the mucinous PCL (Table 1 and Supplementary 
Data). Both SCA cases showed a VHL mutation. Mutations 
detected in cyst fluid were also detected in the surgical 
specimens (data not shown).
Cytology diagnosis and case distribution
Among 318 PCL cases, cytology specimens 
were available for 309 cases. Cytology diagnoses were 
classified into four groups: non-diagnostic (“ND”, 28.8%, 
n = 89), negative for malignancy (“NEG”, 50.5%, n = 
156), atypical/suspicious (“ATY/SUS”, 17.2%, n = 53,), 
and positive for malignancy (“POS”, 3.6%, n = 11). 
Patient demographics are given in Table 2.
Cytology alone has a limited sensitivity for 
mucinous PCN 
In our cohort, the algorithm identified a total of 147 
mucinous PCN and 162 non-mucinous PCL (Table 2). 
The cytology results were compared with the algorithm-
based classification. The cytology analysis alone for 
detecting a mucinous PCN has a sensitivity of 43.5%. Of 
the 147 mucinous PCN with available cytology diagnoses, 
cytology correctly identified 64 cases with a “POS” (n = 
11) or “ATY/SUS” (n = 53) diagnosis but did not detect 
83 cases (“ND”: n = 45, “NEG”: n = 38). Of 162 cases 
negative for mucinous PCN, cytology identified 118 cases 
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Table 1: Summarizes the pathologic, molecular and cytological characteristics of 46 surgical resection specimens of 
pancreatic cystic lesions (PCLs). 
Cyst Type- grade KRAS GNAS Other genes Cytology result
Algorithm
diagnosis
Molecular 
diagnosis*
1- IPMN - LG p.G12V NEG NEG NEG mPCN mPCN
2- IPMN - LG p.G12V p.R201C NEG A/S mPCN mPCN
3- IPMN - LG p.G12V p.R201C NEG A/S mPCN mPCN
4- IPMN - LG p.G12V p.R201H NEG ND mPCN mPCN
5- IPMN - LG p.G12V NEG NEG ND mPCN mPCN
6- IPMN - LG p.G12R NEG NEG A/S mPCN mPCN
7- IPMN - LG p.G12R p.R201H NEG A/S mPCN mPCN
8- IPMN - LG p.G12A p.R201H NEG NEG mPCN mPCN
9- IPMN - LG p.G12R NEG NEG NEG mPCN mPCN
10- IPMN - LG NEG NEG NEG ND mPCN nmPCL
11- IPMN - LG p.G12V p.R201C NEG ND mPCN mPCN
12- IPMN - LG p.Q61H p.R201H NEG ND mPCN mPCN
13- IPMN - MG p.G12D NEG NEG NEG mPCN mPCN
14- IPMN - MG p.G12D p.R201C APC NEG mPCN mPCN
15- IPMN - MG p.G12V p.R201C CDKN2A POS mPCN mPCN
16- IPMN - MG p.G12Ap.G12T
p.R201C
p.R201H NEG ND mPCN mPCN
17- IPMN - MG NEG p.R201C NEG ND mPCN mPCN
18- IPMN - HG p.G12V NEG TP53, PIC3CA A/S mPCN mPCN
19- IPMN - HG NEG NEG BRAF NEG mPCN mPCN
20- MCN - LG p.Q61H NEG NEG NEG mPCN mPCN
21- MCN - LG NEG NEG NEG ND mPCN nmPCL
22- MCN - LG p.G12D NEG NEG A/S mPCN mPCN
23- MCN - LG p.G12D NEG NEG NEG mPCN mPCN
24- MCN - LG NEG NEG NEG ND mPCN nmPCL
25- MCN - MG p.G12D NEG TP53 A/S mPCN mPCN
26- MCN - MG p.G12V NEG NEG NEG mPCN mPCN
27- MCN - MG NEG NEG NEG NEG mPCN nmPCL
28- MCN - MG p.G12D NEG NEG ND mPCN mPCN
29- PDA p.G12R NEG TP53 POS mPCN mPCN
30- PDA p.G12V NEG TP53, SMAD4 POS mPCN mPCN
31- PDA p.G12D NEG SMAD4 POS mPCN mPCN
32- PDA p.G12D NEG RB1, SMAD4, PTEN POS mPCN mPCN
33- PDA p.G12D NEG TP53 POS mPCN mPCN
34- PDA NEG p.R201H SMAD4, TP53 POS mPCN mPCN
35- PDA p.Q61C p.R201C TP53, CDKN2A POS mPCN mPCN
36- PDA p.G12D p.R201H NEG NEG mPCN mPCN
37- SCA NEG NEG VHL NEG mPCN nmPCL
38- SCA NEG NEG VHL NEG nmPCL nmPCL
39- PNET NEG NEG NEG A/S mPCN nmPCL
40- PNET NEG NEG ATM POS mPCN nmPCL
41- PNET NEG NEG NEG A/S mPCN nmPCL
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as “NEG” but could not make a definitive diagnosis in 
44 cases (all “ND”). While it was more likely for a cyst 
to be of non-mucinous subtype in the “NEG” group, the 
distribution of the mucinous PCN and non-mucinous 
PCL cases among non-diagnostic specimens were not 
significantly different (p = 1.00) (Table 2).
Molecular analysis
Non-diagnostic cytology specimens contain KRAS/
GNAS gene mutations
Of cases in the “ND” group 43.7% (38/87) showed 
mutations in KRAS and/or GNAS genes. This fraction is 
significantly higher than KRAS and/or GNAS mutation 
frequency observed in the “NEG” group (23.4%, 36/154, p = 
0.002, Table 3). By contrast, the proportion of specimens with 
KRAS and/or GNAS mutations in “ATY/SUS” and “POS” 
cytology is significantly higher than the “NEG” or “ND” 
groups (85.5%, 53/62, p = 0.0001). At lower frequency, 
other gene mutations were also observed in “NEG” and 
“ND” groups [e.g TP53 (1), PIK3CA (2), ATM (2), APC (2)]. 
Molecular analysis failed in a total of 4 cases in all groups.
Mutant allele frequency (MAF) in non-
diagnostic cytology group is comparable to 
atypical/suspicious cytology group
We compared the KRAS MAF (the most commonly 
mutated and tested gene in our cohort) between different 
42- Pseudocyst/CP NEG NEG NEG NEG nmPCL nmPCL
43- Pseudocyst/CP NEG NEG NEG NEG nmPCL nmPCL
44- Pseudocyst/CP p.G12D NEG NEG NEG mPCN mPCN
45- Pseudocyst/CP NEG NEG NEG NEG nmPCL nmPCL
46- Pseudocyst/CP NEG NEG NEG NEG nmPCL nmPCL
(CP: chronic pancreatitis, IPMN: Intraductal papillary mucinous neoplasm, MCN: Mucinous cystic neoplasm, mPCN: 
mucinous pancreatic cystic neoplasm, nmPCN: non-mucinous pancreatic cystic neoplasm, PDA: Pancreatic ductal 
carcinoma, PNET: Pancreatic neuroendocrine tumor, SCA: Serous cystadenoma, A/S: atypical/suspicious, HG: high-grade, 
LG: low-grade, MG: intermediate grade, ND: non-diagnostic, NEG: Negative, POS: positive)
*Based on the presence or absence of any of the following genes: BRAF, KRAS, GNAS, PIK3CA, CDKN2A, PTEN, SMAD4, 
and TP53.
Table 2: Shows clinical variables of 318 cases of pancreatic cystic lesions
Clinical variable Pancreatic cystic lesions  (n = 318)
Case Distribution:
M = mucinous PCN
NM = non-mucinous PCL
Cytology diagnoses: 
(n of 309, %)
Non-diagnostic “ND”
Negative “NEG”
Atypical/suspicious “ATY/SUS”
Positive “ POS”
(89/309, 28.8%)
(156/309, 50.5%)
(53/309, 17.2%)
(11/309, 3.6%)
M=45 (51%), NM=44 (49%) (p = 1.000)
M=38 (24%), NM=118 (76%) (p = 0.0001)
M=53 (100%), NM=0  (0%) (p = 0.0001)
M=11 (100%), NM=0  (0%) (p = 0.0001)
Female : male 162 : 156 (1.04) M=0.87,  NM=1.19  (p = 0.18)
Patient Age (year),
    Median (range) 61.5, (15 – 93) M=66.8,  NM=56.7  (p = 0.0001)
CEA fluid concentration (ng/ml)  
    Median (range) 1056.5, (0.1 – 11000) M=2126.7, NM=188.9 (p = 0.0001)
Cyst size (mm) 
    Median (range) 33.6, (5 – 114) M=30.2,  NM=36.6  (p = 0.015)
Amylase fluid concentration (u/L),
    Median (range) 6650.3, (2.4 – 24990) M=5061.8, NM=7764.6 (p = 0.008)
Cyst fluid viscosity 
(n = 275)
Viscous   (V)=127
Non-viscous (NV)=148
V, M=91, NM=36
(p = 0.0001)
NV, M=35, NM=113
The univariate analysis is performed between different characteristics in mucinous (M) and non-mucinous (NM) cases 
primarily classified by the proposed algorithm. Statistically significant differences are shown in bold.
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cytology groups. The median KRAS MAF in “ND”, “NEG” 
and “ATY/SUS/POS” groups were 25.3% (range; 2%–
54%), 17.8% (range; 1.5–52.5%) and 25.7% (range; 2%–
88%) respectively. The KRAS MAF observed in the “ND” 
group approached the levels detected in the “ATY/SUS/
POS” group. The difference between “NEG” and “ND” 
groups did not reach the statistical significance (p = 0.086).
ROC curve was then utilized to calculate the KRAS 
MAF threshold for detection of mucinous PCN defined 
by the algorithm (Figure 1). Cytology specimens with 
mutations were divided into low and high MAF groups 
for KRAS based on the ROC-calculated threshold of 1.8%. 
This approach has the potential to improve specificity by 
excluding the incidental finding of precursor lesions such 
as PanIN. In specimens with a KRAS mutation, a low MAF 
was more commonly observed in the “NEG” compared to 
“ND” cytology (p = 0.02, Fisher’s exact test). There was 
no difference in KRAS MAF between “ND” and “ATY/
SUS/POS” (p = 1.000). 
Molecular analysis is more sensitive than 
cytology for detection of mucinous PCN
The molecular analysis results of all PCL cases were 
compared with algorithm-based classification. Of 318 PCL 
cases, molecular analysis for the KRAS gene was performed 
in 303 cases while multi-gene analysis was performed in a 
subset of 182 PCL cases. Any value of KRAS MAF had 
a significantly higher sensitivity for mucinous PCN than 
cytology analysis (82.4% vs. 43.5%, p = 0.0001) without 
adversely affecting the specificity (93.4%). Adding 
GNAS to the gene mutation analysis increased sensitivity 
to 93.3% (Table 4). Interestingly, 27 mucinous PCNs 
showed mutations in additional genes including 25 cases 
with additional KRAS and/or GNAS mutations (Table 
5). Nevertheless, in this study expanding the molecular 
analysis with genes from the Ampliseq cancer hotspot 
panel v2 beyond KRAS and GNAS did not significantly 
improve the detection of mucinous PCN (data not shown).
Table 3: Shows KRAS/GNAS mutation prevalence across different cytology groups
Molecular analysis
Cytology diagnoses
KRAS, n (%) GNAS, n (%) KRAS or GNAS, n (%)
Non-diagnostic “ND” 32/87 (36.8%) 15/51 (29.4%) 38/87 (43.7%)
Negative “ NEG” 32/154 (20.8%) 14/81 (17.3%) 36/154 (23.4%)*
Atypical/suspicious “ATY/SUS” 43/51 (84.3%) 15/34 (44.1%) 44/51 (86.3%)
Positive “ POS” 8/11 (72.7%) 3/9 (33.3%) 9/11 (81.8%)
Note: Patients with more than one mutation are represented in multiple categories. 
(*the presence of a gene mutation is significantly lower in the negative “NEG” group compared to other groups, see text for 
further details).
Figure 1: Receiver operating characteristic (ROC) curve plotted with KRAS mutation allele frequency (MAF) in 
pancreatic cystic lesions classified as either mucinous or non-mucinous based on the clinical algorithm. The purple 
square represents the MAF of 1.8% which showed the best combination of sensitivity and specificity for discriminating mucinous and 
non-mucinous cysts.
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We next examined the impact of using the 1.8% 
cutoff to improve accuracy by separating “high” and 
“low” KRAS MAF. Of the non-mucinous PCL cases with 
a KRAS mutation, 9 of 11 (82%) had an MAF of more than 
1.8% (median = 5.3%; range = 1.47–18). Of the mucinous 
PCN cases with a KRAS mutation, 106 of 117 (93.2%) 
showed MAF of at least 1.8% (median = 26.8%; range 
= 1.2–87.7). Considering only the cases with a “high” 
KRAS MAF as mucinous PCN, a marginal change in the 
sensitivity (82.4% to 79.5%) and specificity (92.4% to 
94.6%) was observed.
Multiple mutations are common in pancreatic 
cystic lesions
Of PCL tested for GNAS and KRAS gene mutations, 
19.8% (36/182) showed both KRAS and GNAS mutations. 
Thirty-five (97%) cases were predicted to have a mucinous 
PCN based on the algorithm-based classification. Among 
cases with double mutations, 33.3% (12/36) have at least 
5% difference in MAF of two different genes. Of these, 
83% (10/12) had a higher KRAS MAF (p = 0.003). In 
addition, 11% (14/127) of mucinous PCN cases carried 
more than one mutation in the same gene (KRAS: 10.4% 
[12/115], GNAS: 6.3% [3/47]). In 7 of 15 cases, the MAF 
differed by at least 5%. These findings may be due to 
presence of multiple cysts, or tumor heterogeneity or 
clonal evolution within a cyst (e.g. KRAS followed by 
GNAS mutation).
The number and frequency of oncogenic 
mutations correlate with dysplasia
Of all the cases with available surgical resections, 
36 cases were either pancreatic adenocarcinoma (PDAC, 
n = 8) or one of its precursors (IPMN, n = 19 and MCN, 
n = 9) (Table 1). Of 36 cases 17 (47%) were low grade 
(LG) lesions (IPMN, n = 12 and MCN, n = 5). These 
cases showed only KRAS (n = 14) and/or GNAS (n = 
7) mutations. No double KRAS or double GNAS gene 
mutation was observed in these LG lesions. Of 9 cases 
(25%) with intermediate grade dysplasia (IPMN, n = 5 
and MCN, n = 4), three (30%) showed mutations in three 
additional genes (TP53, CDKN2A, APC). This group 
also had one case with double mutation in both KRAS 
and GNAS (case #16, Table 1). All PDAC and mucinous 
PCN cases with high grade dysplasia (n = 10), showed 
additional gene mutations (TP53, SMAD4, CDKN2A, 
BRAF, ARID1A, RB1, PTEN, PIK3CA).
DISCUSSION
Incorporation of multiple diagnostic modalities 
such as imaging techniques, cyst fluid chemical analysis 
and clinical findings, although helpful, do not provide 
early detection or accurate differentiation between non-
neoplastic and neoplastic pancreatic lesions [15, 28]. 
Although rare, some mucinous PCNs carry a relatively 
high risk of malignancy. There remains a critical need 
for a better diagnostic tool to stratify patients for proper 
clinical management [29]. Recent studies indicate that 
molecular analysis of the KRAS and GNAS genes may 
be helpful in classifying PCL into neoplastic and non-
neoplastic categories [30, 31]. Although many of these 
recent studies showed the added benefit of presence of 
molecular alterations in oncogenic driver genes, such as 
KRAS, the molecular analysis has not yet found its way 
into the standardized guidelines of pancreatic cystic 
lesions [32]. Here, we demonstrate the value of molecular 
analysis in patients with neoplastic PCL yet classified as 
“negative” or “non-diagnostic” by cytology. In a large 
cohort of PCL, we confirmed that cytologic evaluation 
has limited diagnostic value for low grade PCN [18]. 
In addition, we show that expanding the molecular 
panel beyond the KRAS and GNAS genes was helpful in 
identifying mucinous PCNs with moderate to high grade 
dysplasia.
Considering the surgical cases with mucinous PCN, 
there were a substantial number of cases (27.8%; 10 of 
36) with non-diagnostic cytology. This limitation is similar 
to the previously published studies contributing to the 
low diagnostic sensitivity of cytology [33]. In contrast, 
molecular analysis showed a sensitivity of 88.9% (32 of 
36). Furthermore, 90% of surgically proven PCN with 
non-diagnostic cytology showed at least one mutation 
in KRAS and/or GNAS genes (Table 1). The presence of 
these mutations and the MAF were significantly higher 
in the paucicellular non-diagnostic category than in 
the negative cytology group.  These results suggest the 
molecular analysis is dependent on cell-free DNA, rather 
than cyst-fluid cellularity, and can serve as an important 
complement to morphologic evaluation particularly for 
pancreatic cystic lesions with non-diagnostic cytology. 
In this study, we used an algorithmic approach 
based on international consensus guidelines to classify 
mucinous PCN and non-mucinous PCL [14, 19, 21, 34]. 
Surgical specimens (46/278, 16.5%) were used to assess 
the accuracy of the algorithm in classifying the PCL. 
Final pathologic diagnoses of surgical specimens were 
in agreement with the algorithm (89% concordance). 
When surgical specimens were used as the gold standard 
for the diagnosis of mucinous PCN, the sensitivity of 
cytology and molecular analysis was 41.7% and 88.9%, 
respectively. Cytology and molecular analysis of the 
cohort of 318 specimens classified using the algorithmic 
approach produced similar findings, yielding a sensitivity 
of 43.5% and 93.3%, respectively (table 4). To better 
assess the diagnostic value of cytology, paired analysis 
with surgical resection would be optimal; however, few 
patients need radical surgery. Nevertheless, our data 
support the use of the algorithm to classify PCL into 
mucinous and non-mucinous categories [35]. 
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The algorithm disagreed with molecular analysis 
results in several cases. Eleven cases classified as non-
mucinous PCL by the algorithm, showed KRAS (n = 
10) or GNAS (n = 1) mutations. To improve accuracy 
of molecular analysis, we applied the cut-off of 1.8% 
KRAS MAF obtained from the ROC analysis. However, 
this cutoff value reclassified only 2 of 11 cases as non-
mucinous PCL. While it is possible that these specimens 
represent true mucinous PCN misclassified by the 
algorithm, no follow-up surgical resection was available 
to support this possibility. In addition, 11 cases classified 
as mucinous PCN had KRAS MAF of less than 1.8%. 
These results suggest that use of a MAF cutoff for KRAS 
mutation may have a modest impact on specificity. 
Our study demonstrates that gene mutation analysis 
can help discriminate between non-neoplastic and 
neoplastic cystic lesions. KRAS and GNAS gene analysis 
provided an overall sensitivity for detection of mucinous 
PCN, which was significantly higher than cytology alone 
(93.3% vs. 43.5%, Table 4). In the absence of KRAS 
or GNAS mutations, inclusion of genes such as TP53, 
PTEN, SMAD4, PIK3CA, CDKN2A, BRAF and RB1 
in the molecular analysis identified only one additional 
mucinous PCN. Although this finding suggests expanded 
gene panels may have limited utility for initial diagnosis, 
analysis of additional genes such as RNF43, ATRX and 
DAXX, which were not included in our study, may further 
improve diagnostic sensitivity [35, 36].
Regardless, an expanded gene panel may also 
be informative for dysplasia. Notably, among patients 
with surgical specimens, mucinous PCN with low-grade 
dysplasia showed mutations only in KRAS and/or GNAS 
genes. In contrast, mutations in additional genes were 
observed in mucinous PCN with moderate (3/9, 33%) and 
high grade (9/10, 90%) dysplasia. Both the number and the 
MAF of the of mutated genes increased with the grade of 
dysplasia (Table 1). This finding suggests acquisition of 
additional mutations is associated with progression from 
low grade to high grade dysplasia [37, 38]. The same 
mutations were detected in paired cytology and surgical 
specimens. Consequently, detection of such mutations in 
cytology samples, particularly in non-diagnostic specimens, 
may indicate the presence of a higher grade lesion and 
may warrant consideration for resampling or for surgical 
intervention in the appropriate context [35, 39]. For instance, 
MCN and IPMN with high grade dysplasia both require 
surgical excision; whereas low grade lesions may need 
more conservative approach, such as periodic observation 
for possible progression [40]. As none of the low grade 
mucinous PCN in our study had more than one KRAS and/
or GNAS mutations, in the absence of other indications 
(e.g. grave clinical symptoms, positive cytology), periodic 
monitoring may be sufficient (Table 1). The absence of 
any mutations, nevertheless, did not preclude the need for 
surgery, since this molecular panel is not comprehensive and 
failed to detect PNET and 3 of 9 MCN.
Table 4: Illustrates the comparison between molecular analysis (KRAS or KRAS/GNAS) and cytology analysis for 
detection of a precursor mucinous pancreatic cystic lesion
Gene KRAS KRAS or GNAS Cytology analysis
Number of cases      (303) (182)a  (309) 
Sensitivity:  82.4%* 93.3%* 43.5%
Specificity: 93.4% 83.9% 100%
PPV: 90.7% 84.7% 100%
NPV: 87.0% 92.9%  65.9%
*Sensitivity of molecular analysis is significantly higher than cytology (p = 0.0001).
a182 cases were tested by NGS for both KRAS and GNAS genes.
Table 5: Summarizes the non KRAS/GNAS mutations found in precursor lesions
Mutation type Number of cases with mutation
VHL 8
PIK3CA, TP53 6
ATM 5
SMAD4 4
CDKN2A 3
APC, FGFR3, JAK3 2
RB1, AKT1, ARID1A, MET, FBXW7, ERBB4, PTEN, FGFR2, KIT, SMO 1
The cases with VHL gene mutation are likely to be serous cyst adenomas (SCA).
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Our study has both strengths and limitations. 
The incorporation of cytologic diagnosis into the 
algorithm [14] may artificially increase the specificity of 
cytology in this study. By contrast, molecular analysis 
was not included in the algorithm and consequently 
the sensitivity and specificity of molecular results are 
not affected. The choice of the cyst CEA level may 
also influence the accuracy of the algorithm. Based on 
previous studies, we used a CEA level of 192 ng/ml as a 
threshold for the classification of mucinous PCL [41, 42]. 
In our study ROC analysis for cyst CEA levels suggested 
that the cut off value of 124 ng/ml, rather than 192 ng/
ml, would have the best combination of sensitivity and 
specificity for discriminating between mucinous and 
non-mucinous PCL (supplemental data). Nevertheless, 
the high concordance observed between the algorithm 
and surgical pathology diagnosis supports the use 192 
ng/ml threshold. 
This cohort was followed for a median of 3.3 
years (range 1–8 years). Interestingly, 149 of the 318 
specimens were classified as mucinous PCN by the 
algorithm, yet only 36 patients with mucinous PCN 
had surgical resection. In our study, it is possible that 
some patients may have been lost to follow up, since 12 
patients had other mutations (i.e. AKT1, APC, CDKN2A, 
FGFR2/3, PIK3CA SMAD4 or TP53) in addition to 
KRAS and/or GNAS mutations. Six of these patients had 
atypical/suspicious cytology diagnosis. Nevertheless, 
these results are consistent with the current guidelines 
[14, 21] and support the proposal that many mucinous 
PCN do not require surgical intervention at the time of 
diagnosis [35].
 In summary, the high accuracy of somatic molecular 
analysis of pancreatic cyst fluid, particularly with non-
diagnostic cytology specimens, to identify patients with 
neoplastic PCN which are more likely to benefit from 
surveillance, suggests that the standard of care should 
include somatic mutation analysis in the evaluation of 
pancreatic cystic lesions.
MATERIALS AND METHODS
Case selection
This study (IRB 14071) was approved by 
the institutional review boards of the University of 
Massachusetts Memorial Medical Center, Worcester, MA. 
From January 2008 to October 2015, 318 EUS-guided 
FNA of cyst fluid from 278 patients with pancreatic 
cyst(s) was evaluated during routine clinical testing, with 
follow up until December 2016. Nine specimens were 
not submitted for cytology analysis. Six specimens were 
not submitted for or failed molecular studies. Cyst fluid 
was subjected to chemical, cytopathologic and molecular 
genetic studies. Clinical, radiological and surgical follow-
up data, if available, were recorded. 
Chemical analysis
The cyst fluid CEA (n = 224) levels were tested in 
most patients based on the strong clinical suspicion for 
PCN (Immunoassay (IA) - Quest Diagnostics™). The 
concurrent serum levels were also available for a select 
group of patients. 
Cytopathologic analysis
Cytology slides, prepared from the cyst fluid, were 
stained with the Papanicolaou (Pap) stain [43]. A Diff-
Quik stain was also performed on air-dried smears. Based 
upon the cytology diagnosis, the cases were categorized 
into four groups: non-diagnostic (paucicellular or 
acellular), negative for malignancy, atypical/suspicious 
for malignancy and positive for malignancy [44]. To 
provide sufficient statistical power the atypical/suspicious/
positive cases were grouped together for mutation allele 
frequency (MAF) analysis. These diagnostic categories 
are commonly used for pancreatic solid lesions. Although 
this multitiered reporting system can be applied to cystic 
lesions, it may be less reproducible due to heterogeneity 
and pauci-cellularity [44]. The diagnostic imaging, cyst 
fluid biomarker and endoscopic results and clinical 
impression were accessible prior to the cytopathologists’ 
diagnosis whereas the molecular studies were not.
Molecular analysis
DNA extraction 
To extract DNA from pancreatic cystic fluid, QIAamp 
Circulating Nucleic Acid Kit 55114 (QIAGEN Inc., 
Valencia, CA) was used. Extracted DNA was quantified 
with a UV NanoDrop 1000 spectrophotometer (DNA/RNA 
Calculator, Thermo Scientific, Waltham, MA) to determine 
the A260/A280 ratio. DNA quality was also evaluated using 
endpoint multiplex PCR to ensure DNA fragmentation was 
minimal. To extract DNA from surgical specimens, areas of 
tumor were identified by pathologists (AS, EFC, PAM) and 
manually micro-dissected from formalin-fixed, paraffin-
embedded tissue. The collected cells were digested and 
genomic DNA was extracted as previously described [45]. 
Peptide Nucleic Acid (PNA) clamp PCR
Specific primer sets were used to amplify the region 
of the KRAS gene containing codons 12, 13 and 61, GNAS 
gene containing codon 201 and BRAF gene containing 
codons 598–602. PCR reactions were performed with and 
without a PNA clamp designed to block amplification of 
wild-type sequences (Supplementary Figure 1). In this real 
time PCR assay, the number of PCR cycles between the 
PCR reaction with and without PNA clamp was calculated 
to obtain a delta Ct (∆Ct). If the ∆Ct is ≥ 2 cycles above the 
1% control, the result is reported as wild-type. If ∆Ct is < 2 
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cycles from the 1% control, the result is reported as mutant 
after BigDye Sanger sequencing confirmation (Thermo 
Fisher Scientific Inc., Waltham, MA). Comparing the 
value of ∆Ct in positive control/negative control (100%, 
10%, 1% and 0% of mutation, respectively) with that of 
a patient specimen can be used to quantify the mutation 
levels i.e. if the ∆Ct equals the value of 100% positive 
control, the mutation frequency is 100%. PCR amplicons 
from the PNA reaction were digested with ExoSAP-IT® 
[46]. DNA products were then purified from the Sanger 
sequencing reaction and analyzed using capillary gel 
electrophoresis (ABI 3500xL Genetic Analyzer, Applied 
Biosystems, Foster City, CA) and fluorescence detection. 
This mutation analysis is able to detect the wild-type 
sequence and all known mutations associated with tested 
codons [47]. Results were interpreted using Soft Genetics 
Mutation Surveyor (SoftGenetics, State College, PA). The 
detection limit of the diluted positive control DNA in a 
background of wild-type alleles was 0.01%. 
Next Generation Sequencing (NGS)
Next generation sequencing was performed as 
previously described using Ampliseq cancer hotspot panel 
V2 [48]. Amplicon libraries were created from genomic 
DNA (10 ng) according to the manufacturer’s protocol (Ion 
AmpliSeq Library Kit 2.0, Thermo Fisher Scientific Inc). 
The Ion CHEF Template System (Thermo Fisher Scientific 
Inc.) was used for emulsion PCR to amplify library DNA 
onto IonSphere Particles (ISPs) and load 318v2 chips. 
Sequencing was performed on an Ion Torrent PGM (IC200 
Sequencing Kit, Thermo Fisher Scientific Inc. Waltham, 
MA) with coverage of 500–2500X. Variant calls from two 
software pipelines, Variant Caller V5 (Life Technologies, 
Inc) and NextGene V2 (SoftGenetics, Inc) were compared 
using a laboratory developed visual basic excel program. 
Variants with ≥10 reads and allele frequency greater than 
1% were called positive although the limit of sensitivity is 
0.2%. A manual review of nucleotide sequences was also 
performed for the genes frequently mutated in pancreatic 
cysts. After review, variants were confirmed as somatic 
mutations in the Catalogue of Somatic Mutations in 
Cancer (COSMIC) database [49] or ruled out as a known 
germline single-nucleotide polymorphisms (SNP) with the 
dbSNP database [50]. 
Algorithm to identify mucinous neoplastic cysts
Cytologic diagnosis, cyst fluid CEA levels, cyst size, 
the presence of a mural nodule, fluid viscosity, and EUS 
clinical impression were used in a step-wise algorithmic 
approach to discriminate between mucinous and non-
mucinous PCLs (supplemental data and Supplementary 
Figure 2 for further details). 
Receiver operating characteristics (ROC) curve 
analysis
ROC analysis was used to separate mucinous PCN 
from non-mucinous cysts based on 1) “high” and “low” 
KRAS MAF (defined as relative fraction of mutant PCR 
amplicon in the total DNA amplicon [51] and 2) cyst fluid 
CEA (see Supplemental Data) levels (ng/ml).
The KRAS MAF from cysts classified by the 
algorithm as non-mucinous (n = 165) and mucinous (n = 
146) was plotted on an ROC curve to define a KRAS MAF 
threshold to most accurately separate non-mucinous from 
mucinous neoplastic lesion. 
Statistical analysis
Analysis of statistical difference between categorical 
data in our study was performed based on two-tailed 
Fisher’s exact test. Numerical data was analyzed using the 
Mann-Whitney Exact Test. Sensitivity, specificity, positive 
predictive value, and negative predictive value were 
calculated using standard 2 × 2 contingency tables. p value 
of less than 0.05 is considered significant. ROC calculation 
is performed using GraphPad PRISM 7 software. 
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